Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 5, 2012, Pages 528-537

  Af Björkesten, Clas Göran ^a   Nieminen, Urpo ^a   Turunen, Ulla ^a   Arkkila, Perttu ^a   Sipponen, Taina ^a   Frkkil, Martti ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

adalimumab; calprotectin; CDAI; combined activity index; Crohn's disease; Harvey Bradshaw index; infliximab; SES CD

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; INTERMETHOD COMPARISON; INTESTINE ENDOSCOPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; REMISSION INDUCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84859604934     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.660542     Document Type: Article

References (36)

1. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. (Pubitemid 34784976)
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in populationbased cohorts. Am J Gastroenterol 2010;105:289-97.
3. Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: Where do we stand? Curr Gastroenterol Rep 2010; 12:471-8.
4. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301.
5. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: Infliximab for Crohn's disease treatment -shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69.
6. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976;70:439-44.
7. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122: 512-30. (Pubitemid 34117002)
8. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-69. (Pubitemid 38552790)
9. de Dombal FT, Softley A. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease. International organisation for the study of inflammatory bowel disease. Gut 1987;28:474-81. (Pubitemid 17056886)
10. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl 2):11-17. (Pubitemid 36831453)
11. Jorgensen LG, Fredholm L, Hyltoft Petersen P, Hey H, Munkholm P, Brandslund I. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? Clin Chem Lab Med 2005;43:403-11. (Pubitemid 41460647)
12. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The groupe d'etudes therapeutiques des affections inflammatoires digestives. Gut 1994;35:231-5. (Pubitemid 24092870)
13. Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9.
14. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6. (Pubitemid 351196867)
15. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;315:514.
16. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8:357-63.
17. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. (Pubitemid 38182297)
18. Isaacs KL. How rapidly should remission be achieved? Dig Dis 2010;28:548-55.
19. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8.
20. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'etudes therapeutiques des affections inflammatoires du tube digestif (GETAID). Gut 1989;30:983-9.
21. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD. Gastrointest Endosc 2004;60:505-12. (Pubitemid 39311530)
22. SipponenT,NuutinenH,TurunenU,FarkkilaM.Endoscopic evaluationofCrohn'sdiseaseactivity:comparisonoftheCDEIS and the SES-CD. Inflamm Bowel Dis 2010;16:2131-6.
23. Boivrant M, Leoni M, Taricotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988;10:401-5.
24. Andre C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981;22:571-4. (Pubitemid 11053344)
25. Brignola C, Lanfranchi GA, Campieri M, Bazzocchi G, Devoto M, Boni P, et al. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986;8:245-8. (Pubitemid 16054165)
26. Niederau C, Backmerhoff F, Schumacher B, Niederau C. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997;44:90-107. (Pubitemid 27096020)
27. Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-24.
28. Sipponen T, af Björkesten CG, Farkkila M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010;45: 325-31.
29. Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010;16: 1091-2.
30. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9.
31. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol 2011;46:694-700.
32. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A,Michalsen A, Dobos GJ. Noninvasivemarkers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9.
33. Moskovitz DN, Daperno M, Van Assche G, Baert F, Gevers A, Sostegni R, et al. Defining and validating cut-offs for the simple endoscopic score for Crohn's disease. Gastroenterology 2007;132:S1097.
34. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979;77:843-6. (Pubitemid 9257852)
35. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-13. (Pubitemid 46496634)
36. Walters TD, Steinhart AH, Bernstein CN, Tremaine W, McKenzie M, Wolff BG, et al. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis 2011;17:1547-56.